Provided by Tiger Trade Technology Pte. Ltd.

Marker Therapeutics, Inc.

1.59
+0.01000.63%
Volume:11.68K
Turnover:18.41K
Market Cap:26.51M
PE:-1.36
High:1.60
Open:1.55
Low:1.54
Close:1.58
52wk High:4.07
52wk Low:0.8099
Shares:16.67M
Float Shares:14.12M
Volume Ratio:0.30
T/O Rate:0.08%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1700
EPS(LYR):-1.1950
ROE:-110.67%
ROA:-55.19%
PB:1.44
PE(LYR):-1.33

Loading ...

High Growth Tech Stocks In The US February 2026

Simply Wall St.
·
Feb 12

Marker Therapeutics Receives NIH and CPRIT Funding for Pancreatic Cancer Clinical Trial

Reuters
·
Jan 26

Marker Therapeutics Secures NIH and CPRIT Funding for Pancreatic Cancer Program

Reuters
·
Jan 05

Marker Therapeutics Showcases MAR-T Cell Therapy Advances and MT-601 Clinical Progress in New Corporate Presentation

Reuters
·
Nov 14, 2025

Marker Therapeutics Q3 net loss narrows to $2 mln

Reuters
·
Nov 14, 2025

Marker Therapeutics Q3 EPS USD -0.12

THOMSON REUTERS
·
Nov 14, 2025

Marker Therapeutics Inc: Existing Cash, Cash Equivalents and Restricted Cash Will Fund Operating Expenses Through Q3 of 2026

THOMSON REUTERS
·
Nov 14, 2025

Marker Therapeutics Appoints Kathryn Penkus Corzo to Board of Directors

THOMSON REUTERS
·
Nov 05, 2025

Press Release: Marker Therapeutics appoints Kathryn Penkus Corzo to Board of Directors

Dow Jones
·
Nov 05, 2025

Marker Therapeutics Inc. Files Initial Beneficial Ownership Statement for Director Kathryn Penkus Corzo

Reuters
·
Nov 05, 2025

Marker Therapeutics announces first patient treated in off-the-shelf program

TIPRANKS
·
Oct 06, 2025

Marker Therapeutics Launches Phase 1 Clinical Trial of Off-the-Shelf MAR-T Cell Therapy, Treats First Patient

Reuters
·
Oct 06, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Trump Media, Gold miners, Cracker Barrel

Reuters
·
Aug 26, 2025

BUZZ-Marker Therapeutics jumps after blood cancer trial data

Reuters
·
Aug 26, 2025

Marker Therapeutics Inc. Unveils Presentation on MAR-T Cell Platform and Lead Product MT-601 for Tumor Treatment

Reuters
·
Aug 26, 2025

Marker Therapeutics Inc - Mt-601 Infusion Well Tolerated

THOMSON REUTERS
·
Aug 26, 2025

Marker Therapeutics Inc - No Dose Limiting Toxicities or Icans Observed

THOMSON REUTERS
·
Aug 26, 2025